About 200 reports

They provide rapid pain relief but do not slow disease progression or treat major inflammation.

  • Targeted Therapy
  • Asia
  • World
  • Market Size
  • Galapagos NV

Many of these are long-acting drugs that do not provide immediate pain relief but instead take effect over the course of a number of weeks or months and are administered regularly over a long-term period as a maintenance therapy.

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Prostate cancer: palliative care and pain relief.

  • Targeted Therapy
  • World
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

ANT A HIGH-PRICE TULA RA IS BOTH AN INHIBITOR OF IL-## ADN RE, ONLY LISMTX, US KEY OPINION LEADER ##. ##. ##. ## Dosing and Formulation US KEY OPINION LEADER ##. ##. ##. ## Safety Pipeline Assessment OTHER GENERIC SYSTEMIC THERAPIES, AND ADD-ON PAIN RELIEF MEDICINE.

  • Targeted Therapy
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG

Radiotherapy (RT) is also used to provide effective bone pain relief, with a Cochrane meta-analysis of ## trials finding that ##% of patients can expect to gain a ##% reduction in pain (McQuay et al., 2000).

  • Targeted Therapy
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

The currently marketed branded products are either SC or IV, with the exception of Otezla, MTX, other generic systemic therapies, and add-on pain relief medicine.

  • Targeted Therapy
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

They provide rapid pain relief, but do not slow disease progression or treat major inflammation.

  • Arthritis
  • Targeted Therapy
  • World
  • Market Size
  • Remicade group

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • World
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

RADIOTHERAPY IS ALSO USED TO PROVIDE EFFECTIVE BONE PAIN RELIEF, WITH A COCHRANE META-ANALYSIS OF ## TRIALS FINDING THAT ##% OF PATIENTS CAN EXPECT TO GAIN A ##% REDUCTION IN PAIN (MCQUAY ET AL., 2000).

  • Targeted Therapy
  • Europe
  • Demand
  • Market Size
  • Novartis AG
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

The Phase ## global clinical development program for tanezumab is currently ongoing and includes six studies in approximately ##, ## patients with OA, CLBP or cancer pain who did not experience adequate pain relief with approved therapies.

  • Chronic Pain
  • Targeted Therapy
  • United States
  • World
  • Pfizer Inc.
  • CANAKINUMAB - DRUG PROFILE

Most ACZ## patients (##. ##%) experienced at least a ##% improvement in symptoms vs. ##. ##% for placebo (p ##-May-2011 Novartis announced positive results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ## (canakinumab) provided superior pain relief an

  • Targeted Therapy
  • Turkey
  • United States
  • World
  • Product Initiative
  • canakinumab - Drug Profile

These submissions were based on clinical trials that showed gouty arthritis patients treated with ACZ## at the time of an attack experienced superior pain relief at ## hours and a significant reduction in the risk of new attacks over six months, compared to patients treated with the inject

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Novartis AG

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Bristol-Myers Squibb Company

THE COMPANY OFFERS OVER-THE-COUNTER (OTC) PRODUCTS FOR PAIN RELIEF, ORAL HEALTH, NUTRITION, SKIN HEALTH AND RESPIRATORY DISEASES.

  • Breast Cancer
  • Cancer
  • Targeted Therapy
  • Therapy
  • Amgen Inc.
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Exelixis, Inc.

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Antimalarials
  • Targeted Therapy
  • World
  • Product Initiative
  • Addex Therapeutics Ltd
  • Lung Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Hospital
  • Targeted Therapy
  • United States
  • Product Initiative
  • Merrimack Pharmaceuticals, Inc.

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • MedImmune, LLC

The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases.

  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

The third patient had stable disease on bone scan. ##-Nov-2011 Exelixis, Inc. reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Exelixis, Inc.

The primary outcomes are pain relief by VAS scores of most pain, least pain and average pain by questionnaire.

  • Ophthalmology
  • Targeted Therapy
  • United States
  • Product Initiative
  • Alimera Sciences, Inc.

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Xencor, Inc.